Table 1.
Tumor formation by primary MPNST cells
| Tumor | Injected cell dose (# tumors/# injections) | Cells that formed tumors (%) | 95% CI (%) | ||
|---|---|---|---|---|---|
| 100 cells | 10 cells | 1 cell | |||
| Nf1+/−; Ink4a/Arf−/− mice | |||||
| 10 | 3/3 | nd | 1/8 | 13 | 1.9–95 |
| 11 | 1/2 | 1/2 | 2/6 | 16 | 4.3–61 |
| 12 | 5/5 | 4/6 | 6/8 | 27 | 11–65 |
| 14 | 3/3 | 4/4 | 0/8 | 18 | 6.6–48 |
| 15 | 3/3 | 3/6 | 0/7 | 6.0 | 2.1–18 |
| 16 | 4/4 | 6/6 | 4/10 | 53 | 22–100 |
| 17 | 4/4 | 4/5 | 1/9 | 15 | 5.9–37 |
| 23 | nd | nd | 1/10 | 10 | nd |
| 29 | nd | 2/5 | 1/10 | 6.2 | 1.9–20 |
| 35 | 5/5 | 4/5 | nd | 16 | 5.4–48 |
| TOTAL | 28/29 (97%) | 28/39 (72%) | 16/76 (21%) | 18 | 6.8–55 |
| Nf1+/−;p53+/− mice | |||||
| 1 | 1/3 | 0/4 | 1/10 | 0.7 | 0.1–3.0 |
| 3 | 4/5 | 0/5 | nd | 1.3 | 0.5–3.6 |
| 4 | 4/5 | 2/5 | 1/10 | 2.6 | 1.0–6.8 |
| 5 | 4/5 | 1/5 | 0/10 | 1.7 | 0.6–4.3 |
| 6 | 2/4 | 0/5 | 0/8 | 0.6 | 0.1–2.2 |
| 7 | 5/5 | 3/8 | nd | 5.0 | 1.8–13 |
| 8 | 4/6 | 0/5 | nd | 1.0 | 0.3–2.6 |
| 9 | 0/4 | 0/6 | nd | nd | nd |
| TOTAL | 24/37 (65%) | 6/43 (14%) | 2/38 (5%) | 1.8** | 0.5–4.0 |
Tumorigenic cell frequency significantly differed in this assay between MPNSTs from Nf1+/−; Ink4a/Arf−/− and Nf1+/−;p53+/− mice (**: p=0.008).
nd: not determined.
For tumor histology see Figure S2.